Rachel Haurwitz, the President & CEO of Caribou Biosciences, dives into the future of CRISPR and CAR T therapies. As a pioneer in genome editing, she discusses the transformative potential of off-the-shelf CAR T solutions, currently being tested in multiple clinical trials. Rachel reflects on her journey from co-founding the company at just 26, the importance of strategic partnerships, and navigating the biotech landscape. She also emphasizes the need for diversity and the evolving dynamics in biotech entrepreneurship.
26:25
forum Ask episode
web_stories AI Snips
view_agenda Chapters
menu_book Books
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
Caribou Biosciences Founding
Rachel Haurwitz, Caribou Biosciences CEO, co-founded the company after working in Jennifer Doudna's lab.
She was the first student to work on CRISPR in the lab, calling it the "dark ages" due to limited research.
insights INSIGHT
CAR T-Cell Therapy Challenges and Opportunities
Autologous CAR T-cell therapies offer extraordinary outcomes for some patients, but they are expensive, time-consuming, and logistically complex.
Off-the-shelf CAR T therapies offer improved scalability, accessibility, and cost-effectiveness, expanding treatment reach.
insights INSIGHT
Cost Advantages of Off-the-Shelf Therapies
Manufacturing one autologous CAR T-cell dose per patient incurs high Costs of Goods Sold (COGS).
Off-the-shelf manufacturing dramatically improves COGS by producing hundreds of doses from one run.
Get the Snipd Podcast app to discover more snips from this episode
A Data-Driven Guide to Better, More Relaxed Parenting, from Birth to Preschool
Emily Oster
In 'Cribsheet', Emily Oster applies her economic perspective to the challenges of early parenting. The book debunks myths and conventional wisdom by analyzing research and scientific studies on various parenting issues such as breastfeeding, circumcision, sleep training, and childcare. Oster emphasizes that there is often no single 'right' answer and that decisions should be based on a combination of data and what works best for each family's unique circumstances. The book aims to empower parents with a decision framework, helping them navigate the complexities of parenting with a calm and informed approach.
Synopsis:
Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech.
With four ongoing Phase 1 trials in lymphoma, multiple myeloma, AML, and lupus, Caribou is leading the charge in making CAR T therapies more scalable, accessible, and cost-effective. Rachel also discusses Caribou’s journey from a private startup to a publicly traded company, the role of strategic partnerships like Pfizer’s equity investment, and how biotech companies can navigate today’s uncertain funding landscape.
She reflects on lessons from co-founding Caribou at just 26, the evolution of biotech entrepreneurship, and why raising more capital than you think you need is crucial. Plus, she shares her perspective on leadership, industry trends, and the importance of diversity in biotech, as seen during JPMorgan’s ‘Pink Tuesday’ movement.
From cutting-edge science to strategic decision-making, this episode is packed with insights for biotech professionals, investors, and anyone fascinated by the future of gene editing and cell therapy.
Biography:
Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company’s inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.
Biotech 2050 Podcast 
